doxorubicin hydrochloride

This report, representing the first documented case of LLMS from Central Asia, contributes to the limited global experience with this rare tumor. Our review identified four additional LLMS cases published between 2021 and 2024, totaling five recent reports including the present case. Collectively, these demonstrate persistent male predominance, glottic and supraglottic predilection, and survival outcomes consistent with previous observations. Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients. Continued accumulation and molecular characterization of cases are needed to refine prognostic assessment and optimize management strategies.

P2, N=90, Not yet recruiting, SWOG Cancer Research Network

P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC

To address this, we successfully used DRAQ7, a far-red dye, in HeLa and other cancer cell lines. As our study demonstrates DRAQ7 eliminates auto-fluorescence interference, this approach offers precise differentiation of apoptotic cells and improving experimental and therapeutic reliability.

She was managed according to the Chinese Children Cancer Group (CCCG)-WT-2019 protocol, receiving neoadjuvant VAD (vincristine, actinomycin D, and doxorubicin) chemotherapy, followed by staged bilateral nephron-sparing surgery. This highlights the limitations of current histology- and stage-based approaches for specific molecular subtypes. Current evidence supports more aggressive surgical intervention for high-risk cases, but it is essential to balance the need for renal function preservation with the goal of achieving oncological control.

Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.

The boy had surgery to remove the affected tonsil and lymph nodes, followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Given the tumor's high growth rate and risk of spreading early, treatment needed a team approach that involved complete local removal and immediate systemic therapy. Long-term follow-up is important, and more case reports and studies are necessary to determine the best treatment options and improve results in pediatric histiocytic sarcoma.

Further, functional assays demonstrated that DNX significantly enhanced intracellular accumulation of Calcein-AM in doxorubicin-resistant MCF-7 (MCF-7/DOX) cells in a concentration-dependent manner...In conclusion, DNX significantly inhibits P-gp drug efflux activity and indirectly suppress its expression most probably, through PI3K/AKT/NF-κB signaling modulation. These findings suggest that DNX as a P-gp reversal candidate warranting further preclinical evaluation, including pharmacokinetic and in vivo studies, for the reversal of P-gp-mediated multidrug resistance in cancer.

Compound 17 exhibited the strongest cytotoxic effect against HepG2 cells with an IC50 value of 2.09 μM and a satisfactory SI value of 11.5, which was 5.3- and 6.4-fold higher than the activity of parental tetrandrine and adriamycin, respectively. Moreover, it indicates a potent in vivo killing effect against liver cancers, orthotopically transplanted HCC in an AKT1-dependent manner, with a safety profile. Taken together, compound 17 shows therapeutic potential as a safe anticancer agent through apoptosis induction, worthy of further development.

P2/3, N=345, Active, not recruiting, Pharma Mar S.A. | Recruiting --> Active, not recruiting

Further, CZIF-8/HA demonstrated significantly higher cytotoxicity against cancer cells (HepG-2 and MDA-MB-231) compared to CZIF-8 and doxorubicin, while exhibiting minimal toxicity toward normal MRC-5 cells. These results imply that ZIF-8/HA is a promising nanocarrier for curcumin administration and could be used as a therapeutic strategy for breast and liver cancer treatment.

To address this, a pH-responsive nanoplatform, CDs-DOX-GOX@PEG (CDG@PEG), composed of iron-doped carbon dots (Fe-CDs), doxorubicin (DOX), glucose oxidase (GOX), and polyethylene glycol (PEG), was fabricated to improve CREC treatment through synergistic and targeted therapy...Mechanistically, CDG@PEG realized the CREC therapy by down-regulating drug-resistant genes (such as HIF-1α related genes), inducing mitochondrial dysfunction, and triggering cell apoptosis. This work opened new avenues for developing novel therapeutic strategies against chemotherapy-resistant cancers.